Hypercalcemia Associated with a Malignant Brenner Tumor Arising from a Mature Cystic Teratoma |
| |
Authors: | Michael C. Honigberg Leslie S. Bradford Anand M. Prabhakar Lida P. Hariri Annekathryn Goodman |
| |
Affiliation: | aVincent Obstetrics and Gynecology Service, Division of Gynecologic Oncology, Boston, Mass., USA;bDepartment of Radiology, Boston, Mass., USA;cDepartment of Pathology, Massachusetts General Hospital, Boston, Mass., USA;dHarvard Medical School, Boston, Mass., USA |
| |
Abstract: | A 60-year-old woman presented with abdominal pain and weight loss and was found to have serum calcium of 15.0 mg/dl. Serum parathyroid hormone-related peptide (PTHrP) returned elevated. Imaging suggested bilateral mature cystic teratomas. Her hypercalcemia was treated initially with intravenous saline, as well as intramuscular and subcutaneous calcitonin. She underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, and final pathology revealed malignant Brenner tumor in association with a mature cystic teratoma. Her postoperative PTHrP returned less than assay, and her total and ionized calcium fell below normal, requiring supplemental calcium and vitamin D. At follow-up one month after discharge, her calcium had normalized. We present the first reported case of hypercalcemia occurring in association with a malignant Brenner tumor. Malignancy-associated hypercalcemia occurs via four principal mechanisms: (1) tumor production of PTHrP; (2) osteolytic bone involvement by primary tumor or metastasis; (3) ectopic activation of vitamin D to 1,25-(OH)2 vitamin D, and (4) ectopic production of parathyroid hormone. PTHrP-mediated hypercalcemia is the most common mechanism and was responsible in this case. In patients with paraneoplastic hypercalcemia who undergo surgical treatment, close monitoring and management of serum calcium is necessary both pre- and postoperatively.Key Words: Hypercalcemia, Parathyroid hormone-related peptide, Mature cystic teratoma, Malignant Brenner tumor |
| |
Keywords: | |
|
|